• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Congratulations to the 2026 Fierce AI Innovation Awards Winners

Biktarvy

Bixlenvo
Pharma

Gilead crosses FDA finish line with new HIV combo pill

Gilead Sciences has crossed the regulatory finish line with a new oral treatment option for HIV in the U.S.
Fraiser Kansteiner Aug 27, 2026 5:56pm
Combine

Merck-Gilead first-of-its-kind combo pill scores in 2 HIV trials

Jun 9, 2026 11:20am
Gilead

Gilead says long-acting PrEP Yeztugo in line for $1B in '26 sales

May 8, 2026 11:30am
Gilead

Gilead further pads case for single-tablet HIV med

Feb 25, 2026 1:50pm
Gilead

Gilead's single-tablet HIV combo passes 2nd late-stage test

Dec 16, 2025 9:15am
Gilead

Gilead's bictegravir, lenacapavir tablet meets mark in phase 3

Nov 13, 2025 9:55am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings